Evidence map›Paper›PMID 26717985›Full record

ArticleNucleic acids research2016

The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.

Thomas G Hopkins, Manuela Mura, Hiba A Al-Ashtal, Roni M Lahr, Normala Abd-Latip, Katrina Sweeney, Haonan Lu, Justin Weir, Mona El-Bahrawy, Jennifer H Steel and 4 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 159 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting.International journal of molecular sciences · 2026
    Review
  6. The role ofFrontiers in endocrinology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Biomolecular NMR assignments · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Thomas G HopkinsOvarian Cancer Action Research Centre, Institute of Reproductive and Developmental Biology, Imperial College, London W12 0HS, UK.
Manuela MuraOvarian Cancer Action Research Centre, Institute of Reproductive and Developmental Biology, Imperial College, London W12 0HS, UK.
Hiba A Al-AshtalDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Roni M LahrDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Normala Abd-LatipOvarian Cancer Action Research Centre, Institute of Reproductive and Developmental Biology, Imperial College, London W12 0HS, UK.
Katrina SweeneyOvarian Cancer Action Research Centre, Institute of Reproductive and Developmental Biology, Imperial College, London W12 0HS, UK.
Haonan LuOvarian Cancer Action Research Centre, Institute of Reproductive and Developmental Biology, Imperial College, London W12 0HS, UK.
Justin WeirDepartment of Histopathology, Imperial College Healthcare NHS Trust, London W12 0NN, UK.
Mona El-BahrawyDepartment of Histopathology, Imperial College Healthcare NHS Trust, London W12 0NN, UK.
Jennifer H SteelImperial College Experimental Cancer Medicine Centre, Division of Cancer, Imperial College Academic Health Science Centre, London W12 0NN, UK.
Sadaf Ghaem-MaghamiOvarian Cancer Action Research Centre, Institute of Reproductive and Developmental Biology, Imperial College, London W12 0HS, UK.
Eric O AboagyeComprehensive Cancer Imaging Centre, Imperial College, Du Cane Road, London W12 0NN, UK.
Andrea J BermanDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA AJB190@pitt.edu.
Sarah P BlagdenOvarian Cancer Action Research Centre, Institute of Reproductive and Developmental Biology, Imperial College, London W12 0HS, UK Department of Oncology, University of Oxford, Old Road, Oxford OX3 7LE, UK sarah.blagden@oncology.ox.ac.uk.
University of Pittsburgh · US

Funding

Cancer Research UK 10337Cancer Research UK 12011Cancer Research UK 16584Cancer Research UK 22598Cancer Research UK C2195/A15579Cancer Research UK C37/A7283Cancer Research UK C42671/A12196Department of Health EME/13/122/01Department of Health NIHR/CS/009/009Medical Research Council G0700915Medical Research Council MR/J007986/1Wellcome Trust
6 · The paper itself

Abstract

RNA-binding proteins (RBPs) are increasingly identified as post-transcriptional drivers of cancer progression. The RBP LARP1 is an mRNA stability regulator, and elevated expression of the protein in hepatocellular and lung cancers is correlated with adverse prognosis. LARP1 associates with an mRNA interactome that is enriched for oncogenic transcripts. Here we explore the role of LARP1 in epithelial ovarian cancer, a disease characterized by the rapid acquisition of resistance to chemotherapy through the induction of pro-survival signalling. We show, using ovarian cell lines and xenografts, that LARP1 is required for cancer cell survival and chemotherapy resistance. LARP1 promotes tumour formation in vivo and maintains cancer stem cell-like populations. Using transcriptomic analysis following LARP1 knockdown, cross-referenced against the LARP1 interactome, we identify BCL2 and BIK as LARP1 mRNA targets. We demonstrate that, through an interaction with the 3' untranslated regions (3' UTRs) of BCL2 and BIK, LARP1 stabilizes BCL2 but destabilizes BIK with the net effect of resisting apoptosis. Together, our data indicate that by differentially regulating the stability of a selection of mRNAs, LARP1 promotes ovarian cancer progression and chemotherapy resistance.

Indexed as

Gene Expression ProfilingAnimalsAntineoplastic AgentsAutoantigensBlotting, WesternCarcinogenesisCell Line, TumorCell SurvivalDisease ProgressionDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHeLa CellsHumansInterleukin Receptor Common gamma SubunitMice, Inbred NODAntineoplastic AgentsAutoantigensIl2rg protein, mouseInterleukin Receptor Common gamma SubunitRibonucleoproteinsSS-B Antigen

Identifiers

PMID26717985
PMCPMC4756840
OpenAlexW2231236206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.